REGENERON PHARMACEUTICALS INC financial statements, including revenue, expenses, profit, and loss
The total revenue of RGO for the last quarter is 3.15 B CHF, and it's 1.13% lower compared to the previous quarter. The net income of Q3 24 is 1.14 B CHF.